Protease Engineering Platform
- Catalyst Biosciences Reports First Quarter 2021 Operating & Financial Results and Provides a Corporate Update– click to read
- Catalyst Biosciences Announces First Patient Dosed in Pivotal Phase 3 Registration Study of SQ MarzAA in Individuals with Hemophilia A or B with Inhibitors– click to read
- Catalyst Biosciences Announces Publication of CB 2679d Preclinical FIX Gene Therapy Data in Blood, the Journal of the American Society of Hematology– click to read
The Catalyst Advantage
Drug candidates for severe medical conditions
Learn more about the medicines we are developing
Addressing diseases with unmet medical needs
Share our passion about treating disease
Experienced and passionate team
Learn more about the Catalyst team and mission/culture
